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Abstract. 
 
AU-rich elements (AREs) present in the 3
 
9
 
untranslated regions of many protooncogene, cytokine,
and lymphokine messages target them for rapid degra-
dation. HuR, a ubiquitously expressed member of the
ELAV (embryonic lethal abnormal vision) family of
RNA binding proteins, selectively binds AREs and sta-
bilizes ARE-containing mRNAs in transiently trans-
fected cells. Here, we identify four mammalian proteins
that bind regions of HuR known to be essential for its
ability to shuttle between the nucleus and the cyto-
plasm and to stabilize mRNA: SET
 
a
 
, SET
 
b
 
, pp32, and
acidic protein rich in leucine (APRIL). Three have
been reported to be protein phosphatase 2A inhibitors.
All four ligands contain long, acidic COOH-terminal
tails, while pp32 and APRIL share a second motif: rev-
like leucine-rich repeats in their NH
 
2
 
-terminal regions.
We show that pp32 and APRIL are nucleocytoplasmic
shuttling proteins that interact with the nuclear export
factor CRM1 (chromosomal region maintenance pro-
tein 1). The inhibition of CRM1 by leptomycin B leads
to the nuclear retention of pp32 and APRIL, their in-
creased association with HuR, and an increase in
HuR’s association with nuclear poly(A)
 
1
 
 RNA. Fur-
thermore, transcripts from the ARE-containing c-
 
fos
 
gene are selectively retained in the nucleus, while the
cytoplasmic distribution of total poly(A)
 
1
 
 RNA is not
altered. These data provide evidence that interaction of
its ligands with HuR modulate HuR’s ability to bind its
target mRNAs in vivo and suggest that CRM1 is instru-
mental in the export of at least some cellular mRNAs
under certain conditions. We discuss the possible role of
these ligands upstream of HuR in pathways that govern
the stability of ARE-containing mRNAs.
Key words: AU-rich elements • RNA stability • nu-
cleocytoplasmic shuttling • CRM1 • protein phos-
phatase inhibitors
 
Introduction
 
Messenger RNA degradation is a mechanism by which eu-
karyotic cells regulate gene expression and influence cell
growth and differentiation (Sachs, 1993). It is dependent
upon both cis-elements in the RNA and trans-acting fac-
tors. The best-characterized cis-element in mammalian
messages is the AU-rich element (ARE)
 
1
 
 (Chen and Shyu,
1995). AREs are present in the 3
 
9
 
 untranslated regions of
many mRNAs, including those of proto-oncogenes, cyto-
kines, and lymphokines, and target these RNAs for rapid
degradation (Caput et al., 1986; Shaw and Kamen, 1986).
Direct or indirect interactions of these sequences with spe-
cific protein factors are believed to govern mRNA half-life.
The overexpression of HuR stabilizes messages contain-
ing AREs in transient transfection experiments (Fan and
Steitz, 1998a; Peng et al., 1998). HuR (or HuA) is a ubiqui-
tously expressed member of the ELAV (embryonic lethal
abnormal vision) family of RNA binding proteins (Good,
1995; Ma et al., 1996), originally identified in 
 
Drosophila
 
as essential for neural development (Campos et al., 1985).
There are three neural-specific Hu family members in
mammals: HuB (or HelN1/N2) (Akamatsu et al., 1999;
Jain et al., 1997), HuC (Akamatsu et al., 1999), and HuD
(Chung et al., 1997). All four Hu proteins contain three
RNA recognition motifs (RRMs). Both gel shift (Myer et
al., 1997) and UV–cross-linking (Fan et al., 1997) experi-
ments have provided evidence that HuR binding parallels
the in vivo ability of ARE sequences to direct mRNA deg-
radation. ARE recognition appears to be mediated by the
first two RRMs of HuR; the third RRM has been sug-
gested to bind the poly(A) tail (Ma et al., 1997). In tran-
sient transfection assays, deletion of RRM3 alone abol-
ishes HuR’s ability to stabilize ARE-containing reporter
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mRNAs (Fan and Steitz, 1998a). Although predominantly
nuclear, HuR shuttles between the nucleus and the cyto-
plasm by virtue of a novel shuttling sequence, HNS, lo-
cated in the hinge region between its second and third
RRM (Fan and Steitz, 1998a,b). This has led to the sugges-
tion that HuR may initially bind mRNAs in the nucleus
and accompany them into the cytoplasm to provide ongo-
ing protection from the degradation machinery. Recent in
vivo cross-linking experiments and gradient analyses es-
tablished that HuR can bind poly(A)
 
1
 
 RNA in both cellu-
lar compartments and that a substantial fraction of cyto-
plasmic HuR is found associated with polysomes (Gallouzi
et al., 2000).
ARE-mediated mRNA stability is subject to regulation.
Cell stress (Gorospe et al., 1998), stimulation (Lindsten et
al., 1989; Ming et al., 1998), and transformation (Hirsch et
al., 1995) have all been shown to stabilize ARE-containing
mRNAs. Several lines of evidence suggest the involve-
ment of signal transduction pathways. Stimulation of qui-
escent primary T cells with antibodies directed against
CD3/CD28 receptors stabilizes several mRNAs containing
AREs (Lindsten et al., 1989). The stabilization of ARE-
containing mRNA has been associated with the activation
of c-jun NH
 
2
 
-terminal kinase, which is correlated with
lower decay rates of IL-3 mRNA in mast cells (Ming et al.,
1998). Stabilization has also been linked to the activation
of MAP kinase-activated protein kinase 2 (Dean et al.,
1999; Winzen et al., 1999) in HeLa cells. Phosphatases, like
kinases, have been implicated in ARE-mediated stability.
Cyclosporin A, an antagonist of calcineurin (protein phos-
phatase 2B), destabilizes IL-3 mRNA in autocrine tumor
cell lines (Nair et al., 1994). However, the molecular de-
tails by which any of these pathways impact mRNA stabil-
ity is not known. Considering the multiple players and
their various cellular roles, the mechanisms are likely to be
complex.
To begin to understand molecular interactions underly-
ing the regulation of ARE-mediated mRNA stability, we
looked for HuR binding partners. Here, we use affinity
chromatography to identify four protein ligands to HuR in
HeLa cell extracts. All of these proteins contain unusually
long acidic stretches at their COOH termini. Although ini-
tially recognized in other contexts, three of the ligands
have been reported to be inhibitors of protein phos-
phatase 2A (PP2A) (for review, see Millward et al., 1999).
We have examined the subcellular location and trafficking
of these ligands and have delineated the nature of their in-
teractions with HuR. We provide evidence for the in vivo
association of HuR with these ligands, as well as data sug-
gesting that their association modulates HuR interactions
with ARE-containing mRNAs.
 
Materials and Methods
 
Plasmid Constructions
 
Plasmids described in this manuscript were synthesized using oligonucle-
otides containing restriction sites adjacent to the coding regions. Ampli-
fied products were digested with the appropriate enzymes and cloned into
their respective vector(s). Two glutathione-S-transferase (GST)–HuR
constructs were used. That encoding the protein used in the initial purifi-
cation (see Fig. 1 B) was created by amplifying human HuR cDNA from
pcDNA3-HuR (Fan and Steitz, 1998a) and inserting it into the BglII and
EcoRI sites of pGEX-2TK (Amersham Pharmacia Biotech) to form an in-
frame fusion with GST. The second GST-HuR construct and mutants 1–5,
used in the in vitro binding assays, have been reported (Gallouzi et al.,
2000). Like these constructs, the remaining HuR mutants were created by
amplifying portions of HuR (see Fig. 4, legend) from pcDNA3-HuR (Fan
and Steitz, 1998a) and inserting them into the EcoRI and NotI sites of
pGEX-5X-2 (Amersham Pharmacia Biotech) to form in-frame fusions
with GST. SET
 
b
 
, pp32, and acidic protein rich in leucine (APRIL) cDNAs
were amplified from a human kidney library (kindly provided by R. Lif-
ton, Howard Hughes Medical Institute, Yale University, New Haven,
CT). The cDNAs encoding SET
 
b
 
 and a truncated form of APRIL (amino
acids 1–194) were inserted into the EcoRI and NotI sites of pGEX-5X-2.
pp32 cDNA was inserted into the BamHI and NotI sites of the same vec-
tor. pp32-Flag and APRIL-Flag were created by amplifying their cDNAs
with a downstream oligonucleotide containing the eight–amino acid Flag
sequence and inserting them into the EcoRI and NotI, or BamHI and
NotI sites of pcDNA3, respectively. Truncated portions of pp32 (see Fig.
4, legend) were created by PCR and inserted into the BamHI and NotI
sites of pcDNA3. All oligonucleotide sequences can be obtained from the
authors upon request.
 
Recombinant Protein Expression, Purification, and In 
Vitro Binding Assay
 
Plasmids for bacterial expression were transformed into BL21 cells. The
protocol for the growth, induction, and lysis of these cells has been re-
ported (Frangioni and Neel, 1993). The purification of the GST fusion
proteins followed the protocol supplied by pGEX manufacturer (Amer-
sham Pharmacia Biotech).
In vitro transcription and translation was performed using the TNT T7
Quick-Coupled Transcription/Translation System (Promega) in accor-
dance with the protocol supplied by the manufacturer.
For the in vitro binding assays, affinity matrices were prepared by satu-
rating 10 
 
m
 
l of packed glutathione sepharose beads with one of the tagged
versions of HuR. After purification, the matrix was reequilibrated with 20
mM Hepes, pH 7.9; 100 mM KCl, and incubated with either 200 
 
m
 
l of HeLa
nuclear extract (see Fig. 4, A and B) or equimolar amounts of the in vitro
translated proteins (as judged by autoradiography) (see Fig. 4 C) at 4
 
8
 
C for
1 h. The beads were then washed with two 1-ml volumes of the reequilibra-
tion buffer. Bound material was eluted with 20 mM Hepes, pH 7.9, and 1 M
KCl, and TCA precipitated before loading on gels.
 
Purification and Identification of HuR Binding Proteins
 
After purifying GST-HuR in batch, 
 
z
 
2.5 mg of the protein (as judged by
SDS-PAGE analysis with reference to standards), bound to the glutathione
sepharose, was packed into a column and re-equilibrated with 50 column
volumes of 20 mM Hepes, pH 7.9, 100 mM KCl. Afterwards, RNase-treated
nuclear extract derived from 5.5 
 
3
 
 10
 
9
 
 HeLa cells (Dignam et al., 1983) was
slowly passed over the column (5 ml/h) and the column was washed with re-
equilibration buffer. Interacting proteins were eluted with a 0.1–2 M KCl
gradient. Protein identification was performed by the Keck Foundation
Biotechnology Resource Laboratory at Yale University. The peptides rec-
ognized by mass spectrometry or Edman sequencing are as follows: SET
 
a
 
:
155–167; SET
 
b
 
: 11–26, 12–26, 27–44, 45–55, 60–70, 65–70, 71–77, 110–119,
124–137, 142–154, 169–176; pp32: 6–12, 7–12, 21–28, 68–75, 69–75, 100–110,
100–111, 102–111, 111–116, 138–150, 138–153, 238–249; APRIL: 6–12, 7–12,
68–75, 69–75, 76–87, 87–99, 100–110, 100–111, 102–110, 102–111, 117–132,
138–150. Isoelectric points were calculated using the pI/Mw program, part
of the Swiss Institute of Bioinformatics’ Expert Protein Analysis System.
The amount of RNase A used in treating the nuclear extract was deter-
mined by titration. Extract was incubated with varying amounts of RNase
A at 25
 
8
 
C for 15 min. Subsequently, the RNA in each sample was pCp la-
beled and its degradation assessed by gel fractionation. 1 
 
m
 
g of enzyme
was sufficient to digest the RNA from 10
 
6 
 
HeLa cells.
 
Antibodies, Immunoblotting, and Quantitation
 
Recombinant GST-SET
 
b
 
, GST-pp32, and a GST-tagged truncated form
of APRIL (amino acids 1–194) were expressed and purified as described
above, and dialyzed against PBS. Rabbits were injected with 500 
 
m
 
g of the
proteins at 3-wk intervals by Yale University’s Immunization Services.
Antibodies were purified by affinity chromatography: serum was passed
through two columns sequentially, the first containing GST (Amersham
Pharmacia Biotech) to remove anti–GST antibodies and the second con- 
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taining the antigen to obtain the purified antibody. Both columns were
prepared by conjugating the proteins to cyanogen bromide–activated
Sepharose (Amersham Pharmacia Biotech) following the manufacturer’s
protocol. The flow-through from the first column was applied to the sec-
ond. The purified antibodies were obtained by eluting the second column
with 100 mM Tris, pH 2.5 (Harlow and Lane, 1988).
For immunoblot analysis, proteins were fractionated on 12% denatur-
ing polyacrylamide gels and transferred to nitrocellulose. Proteins derived
from human tissues were obtained from CLONTECH Laboratories, Inc.
The blots were probed as described (Gallagher et al., 1994). The anti–
ligand antibodies were used at 1:5,000; the anti–CRM1 (chromosomal re-
gion maintenance protein 1; kindly provided by G. Grosveld, St. Jude
Children’s Research Hospital, Memphis, TN) (Fornerod et al., 1997a) was
used at 1:1,000; the 4B10 anti–hnRNP A1 (kindly provided by S. Pinol-
Roma, Mount Sinai School of Medicine; New York, NY) was used at
1:1,000; the 3A2 anti–HuR antibody (Gallouzi et al., 2000) was used at
1:30,000. The secondary antibody was either HRP-conjugated donkey
anti–rabbit or HRP-conjugated donkey anti–mouse. The blots were devel-
oped using the ECL system (Amersham Pharmacia Biotech) according to
the manufacturer’s directions.
All quantitations were performed using the National Institutes of
Health image 1.62 program.
 
Cell Lysate, Glycerol Gradient, and 
Coimmunoprecipitation Assays
 
HeLa whole-cell lysate known to preserve complexes was prepared at
1.5 
 
3
 
 10
 
8
 
 cells/ml as described (Gu et al., 1997) and was clarified by cen-
trifugation at 40,000 rpm for 40 min. The supernatant was loaded onto 4
ml 5–20% glycerol gradients made with 10 mM triethanolamine, pH 7.9,
100 mM KCl, 5 mM MgCl
 
2
 
, and 1 mM DTT, and centrifuged at 40,000 rpm
(SW50.1 rotor; Beckman Coulter) for 12 h. Immunoprecipitations were
performed from gradient fractions as described (Gallouzi et al., 1998), ex-
cept that each fraction was diluted threefold in lysis buffer (Gu et al.,
1997) before incubation with the antibody.
 
Cell Culture and Transient Transfections
 
Suspension HeLa cells were obtained from the National Cell Culture Cen-
ter. Adherent HeLa cells and murine L929 cells were maintained in MEM
medium (GIBCO BRL) supplemented with 10% fetal bovine serum
(GIBCO BRL).
Adherent HeLa cells were transfected by incubating them with a cal-
cium phosphate precipitate of the plasmid of interest (Loflin et al., 1999).
 
Heterokaryon Formation, Immunofluorescence 
Microscopy, In Situ Hybridization, and In
Vivo Cross-linking
 
The immunofluorescence protocol has been reported (Fan and Steitz,
1998a). The anti–Flag monoclonal antibody M2 (Sigma-Aldrich) was di-
luted to 10 
 
m
 
g/ml. The anti–Myc monoclonal antibody (Sigma-Aldrich)
was used at a 1:1,000 dilution. The polyclonal antibodies were used at 
 
z
 
5
 
m
 
g/ml. Two secondary antibodies were used, both at concentrations of 6–8
 
m
 
g/ml: Alexa 488 conjugated anti–mouse (Molecular Probes) and Texas
red conjugated anti–rabbit (Molecular Probes). Hoechst dye 33258
(Sigma-Aldrich) was included with the secondary antibodies at 1 
 
m
 
g/ml.
HeLa and L929 fusions were formed as described (Fan and Steitz,
1998a). Leptomycin B (kindly supplied by M. Yoshida, The University of
Tokyo, Tokyo, Japan) was used at a concentration of 10 ng/ml.
In situ
 
 
 
localization of poly(A)
 
1
 
 RNA has been described (Gallouzi et
al., 2000). For in situ localization of specific mRNAs, the cells were serum
starved for 24 h and leptomycin B (LMB) was added (5 ng/
 
m
 
l) 8 h before
serum stimulation. 30 min after serum stimulation, the cells were fixed and
permeabilized (Gallouzi et al., 2000). 5 ng/
 
m
 
l of message-specific oligonu-
cleotide probes [two for c-
 
fos
 
 (Calbiochem and gift of J.-L. Veyrune, Insti-
tut de Genetique Moleculaire de Montpellier, CNRS, Montpellier,
France) and one for GAPDH (Calbiochem)] were used to establish the
c-
 
fos
 
 and GAPDH mRNA cellular distribution. The probes had been pre-
viously 3
 
9
 
-end labeled with digoxigenin according to the protocol supplied
by Boehringer. In situ hybridization was performed according to Gallouzi
et al. (2000).
In vivo cross-linking was performed as described (Pinol-Roma et al.,
1989).
 
Results
 
Affinity Purification of Four Previously Identified 
Proteins as HuR Ligands
 
Potential complexes containing HuR were examined by
density gradient centrifugation. HeLa whole-cell extract
was prepared in a manner known to preserve complexes
(Gu et al., 1997), but treated with ribonuclease A (RNase
A, see Materials and Methods) to prevent RNA from teth-
ering HuR to other RNA binding proteins. After fraction-
ation on a 5–20% glycerol gradient, immunoblots were
probed with the 3A2 anti–HuR monoclonal antibody
(Gallouzi et al., 2000). This analysis revealed that endoge-
nous HuR (36 kD) is dispersed throughout the gradient
(Fig. 1 A, top), in contrast to the discrete profile of His-
tagged recombinant HuR (bottom). These data suggest
that HuR in HeLa cells may engage in several complexes
not mediated by RNA.
We used affinity chromatography to identify HuR bind-
ing partners. Human HuR cDNA was subcloned down-
stream of the glutathione-S-transferase coding region to
Figure 1. HuR exists in complexes and interacts with four pro-
tein ligands in vitro. (A) HeLa whole-cell extract (Gu et al., 1997)
was fractionated on a 5–20% glycerol gradient. Fractions were
run on a 12% gel and immunoblots probed with the 3A2 anti–
HuR antibody (Gallouzi et al., 2000). As markers, phosphorylase
B (104 kD), ovalbumin (48 kD), and carbonic anhydrase (33 kD)
were run on a parallel gradient. (B) To identify HuR binding pro-
teins, GST-HuR was immobilized on glutathione Sepharose
(Amersham Pharmacia Biotech) and incubated with HeLa nu-
clear extract pretreated with RNase A. After washing, bound
proteins were eluted from the column with a KCl gradient (0.1–2
M), fractionated on a 12% denaturing gel, and visualized by sil-
ver staining. Fractions were pooled, run on a second gel, and the
indicated proteins were identified (see Materials and Methods). 
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form an in-frame fusion. This fusion protein, which mimics
HuR binding to RNA in UV–cross-linking and competi-
tion experiments (data not shown), was expressed in
bacteria and purified on glutathione sepharose. RNase
A–treated HeLa nuclear extract (Dignam et al., 1983)
from 5.5 
 
3
 
 10
 
9
 
 cells was passed over the GST-HuR column
(since HuR is predominantly nuclear; Fan and Steitz,
1998a) and, after washing, bound proteins were eluted
with a 0.1–2 M KCl gradient. 1/10 of each fraction was ana-
lyzed by SDS-PAGE followed by silver staining (Fig. 1 B),
showing several proteins that peak at 
 
z
 
250 mM KCl.
None of these proteins bound to either the GST protein
alone or the column matrix (data not shown). The remain-
der of fractions 5–10 were pooled, run on a second gel, and
stained with Coomassie brilliant blue. The four proteins
denoted in Fig. 1, ranging from 
 
z
 
28 to 
 
z
 
45 kD, were ex-
cised from the gel, treated with trypsin, and analyzed by a
combination of mass spectrometry and Edman degrada-
tion sequencing (see Materials and Methods).
Each of the four proteins (Fig. 2) had been previously
described and three had been given several different
names. We use either the protein’s original name or that
most commonly seen in the literature: SET
 
a
 
/
 
b
 
 (von
Lindern et al., 1992; Matsumoto et al., 1993), pp32 (Malek
et al., 1990), and acidic protein rich in leucine (APRIL;
Mencinger et al., 1998). Three of these proteins (SET
 
a
 
,
SET
 
b
 
, and pp32) had been identified as inhibitors of
PP2A (Li et al., 1996; Saito et al., 1999). Their other re-
ported activities are detailed in the Discussion.
The four HuR binding proteins exhibit striking struc-
tural similarity (Fig. 2). All contain a long, acidic COOH-
terminal tail: residues 242–290 of SET
 
a
 
, 222–277 of SET
 
b
 
,
164–249 of pp32, and 162–251 of APRIL. These tails prob-
Figure 2. Sequences of the HuR binding proteins. Sequences
shaded in black indicate identities, while gray denotes similari-
ties. pp32 contains two rev-like leucine rich repeats (residues 63–
71, and 112–120), whereas APRIL contains three (residues 61–
69, 85–93, and 110–118). The calculated molecular weights of
SETa, SETb, pp32, and APRIL are: 33.5, 32.1, 28.6, and 28.8 kD,
respectively. Note that APRIL migrates faster than pp32 in SDS-
PAGE despite the fact that it is two amino acids longer. Residue
three of our SETa cDNA clone is different from that reported
(proline; Nagata et al., 1995).
Figure 3. Coimmunoprecipitation of HuR from a glycerol gradi-
ent of HeLa whole-cell extract using antiligand antibodies. HeLa
whole-cell extract was prepared and fractionated on a glycerol
gradient as described in Fig. 1. A portion of each fraction was elec-
trophoresed on a 12% denaturing gel, transferred to nitroceullose,
and probed with antiligand antibodies (see Materials and Meth-
ods). 10-fold larger portions were immunoprecipitated with anti–
SET (A), anti–pp32 (B), or anti–APRIL (C). These precipitates
were analyzed as above, but probed with the 3A2 anti–HuR mono-
clonal antibody. One gradient was used for all of the results in this
figure. The molecular weight markers are described in Fig. 1. 
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ably contribute to the proteins’ mobilities in SDS-poly-
acrylamide gels (Fig. 1 B), which are slower than predicted
from their molecular weights (Fig. 2, legend) (Graceffa et
al., 1992). The calculated isoelectric points for SET
 
a
 
,
SET
 
b
 
, pp32, and APRIL are accordingly low: 4.23, 4.12,
3.99, and 3.94, respectively. Beyond their common acidic
regions, the HuR binding proteins divide into two subsets:
SET
 
a
 
 and SET
 
b
 
, and pp32 and APRIL. SET
 
a
 
 and SET
 
b
 
are identical over their 253 COOH-terminal amino acids,
diverging only for the first 37 amino acids of SET
 
a
 
 and the
first 24 amino acids of SET
 
b
 
; thus, these proteins are prob-
ably splice variants of one another, as previously noted
(Matsumoto et al., 1993). In contrast, pp32 and APRIL ex-
hibit 71% sequence identity (Fig. 2, black boxes) and 81%
sequence similarity (gray boxes) and are clearly products
of separate genes. They contain a second structural simi-
larity: rev-like leucine-rich repeats in their NH
 
2
 
-terminal
regions (see Fig. 2, legend, and below).
We examined the tissue distribution of the four HuR
binding proteins in various human tissues by immunoblot-
ting (see Materials and Methods) and found, in agreement
with reports on several mammalian species, that each is se-
lectively expressed in certain tissues. The SET proteins are
present in brain, heart, lung, spleen, and kidney (data not
shown) (Nagata et al., 1998). pp32 is expressed in brain
(Matsuoka et al., 1994) and kidney (data not shown), as
well as in cells capable of self-renewal, such as those of the
intestinal crypts and prostate (Kadkol et al., 1998; Malek
et al., 1990). APRIL is present in brain, kidney, liver, skel-
etal muscle, and testis (data not shown) (Mencinger et al.,
1998). It has been previously observed that HuR is several-
fold more abundant in mammalian tissue culture cells that
divide most rapidly (Fan and Steitz, 1998a). This is also
true of all four HuR binding proteins (data not shown).
 
Detection of Complexes between HuR and Its Ligands 
in Cell Extract
 
Polyclonal antibodies were raised against GST-tagged ver-
sions of SET
 
b
 
, pp32, and a portion of APRIL (see Materi-
als and Methods). These antibodies were affinity purified
(Materials and Methods) and used to probe the gradient-
fractionated, RNase-treated cell extract analyzed in Fig. 1
A. The four ligands are dispersed throughout the gradient
(Fig. 3, A–C, top), suggesting that they, like HuR, are in-
volved in multiple complexes. As anticipated, polyclonal
antibodies directed against SET
 
b
 
 cross-react with SET
 
a
 
.
The interaction of HuR with its ligands in these gradi-
ents was confirmed by immunoprecipitating each fraction
with antisera to the various ligands, followed by probing
immunoblots of the precipitates with the monoclonal 3A2
anti–HuR antibody (Gallouzi et al., 2000). Fig. 3, A–C
(bottom), reveals that SET
 
a
 
 and/or SET
 
b
 
 interact with
HuR in complexes with a range of sizes that might include
additional proteins. In contrast, pp32- and APRIL-con-
taining complexes are smaller and more discrete (peaking
at 50–60 kD), suggestive of simple heterodimeric interac-
tions with HuR.
Immunoprecipitations performed on unfractionated
HeLa whole-cell extract revealed that 
 
z
 
5% of total cellu-
lar HuR binds to each of these four ligands (data not
shown). Since no hnRNP A1, another RNA-binding pro-
tein that is at least 100-fold more abundant than HuR
(Kiledjian et al., 1994), was detected in these same precipi-
tates (data not shown), we conclude that HuR’s interac-
tions with SET
 
a
 
/
 
b
 
, pp32, and APRIL are highly specific.
The converse immunoprecipitation experiments (in which
HuR was quantitatively immunoprecipitated and the pre-
Figure 4. RRM3 and the hinge region of HuR are required for
ligand binding, while the acidic tail of pp32 binds HuR. (A and
B) Eight deletion mutants of GST-HuR were overexpressed in
Escherichia  coli, purified on glutathione sepharose, and incu-
bated with HeLa nuclear extract treated with RNase A. The
beads were then washed and the ligands were eluted, run on a
12% denaturing gel, transferred to nitrocellulose, and probed
with affinity purified antibodies to SETa/b, pp32, or APRIL. FL
denotes full length HuR (326 amino acids) fused to GST. Those
amino acids of HuR included in the mutants are as follows: M1,
2–242; M2, 2–189; M3, 2–100; M4, 19–326; M5, 101–326; M6, 190–
326; M7, 243–326; M8, 190–242. (C) Plasmids encoding full-
length pp32 (249 amino acids, lane 1), its NH2-terminal region
(amino acids 1–167, lane 2), and its acidic tail (amino acids 168–
249, lane 3) were transcribed and translated in vitro in the
presence of 35S-methionine and incubated with GST-HuR on
glutathione sepharose. Bound polypeptides were run on a dena-
turing gel and detected by autoradiography (lanes 4–6). While
the migration of all pp32 polypeptides is retarded (presumably
because of their acidic nature), that of the acidic tail (amino acids
168–249, lanes 3 and 6) is most retarded. 
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cipitates probed for the four binding proteins) indicated that
SET
 
a
 
, SET
 
b
 
, pp32, and APRIL are at least 10-fold more
abundant than HuR in HeLa cells (data not shown); thus,
only a small fraction of each ligand is associated with HuR.
 
RRM3 and the Hinge Region of HuR Are Required for 
Ligand Binding
 
Previous studies have shown that RRM3 is crucial for
HuR’s ability to stabilize ARE-containing mRNAs (Fan
and Steitz, 1998a) and that its hinge region contains a
nucleocytoplasmic shuttling sequence (Fan and Steitz,
1998b). To ask whether interactions between HuR and
SET
 
a
 
, SET
 
b
 
, pp32, and APRIL involve these important
regions, the ligands’ binding sites on HuR were mapped by
deletion analysis (Fig. 4, A and B). Eight HuR mutants,
designed to preserve conserved domains (as defined by
Okano and Darnell, 1997), were subcloned downstream of
GST. The resulting fusion proteins were immobilized on
glutathione sepharose, incubated with RNase A–treated
HeLa nuclear extract, and their ability to bind the HuR
ligands examined by immunoblotting with affinity purified
anti–ligand antibodies.
Fig. 4, A and B, shows that while all four HuR binding
proteins interact robustly with GST-tagged full-length
HuR (lane 1), removal of HuR’s third RRM (lane 2), or
longer sequences from the COOH terminus (lanes 3 and
4) completely abolishes ligand binding. This is not the case
for deletions that remove the NH
 
2
 
 terminus or the first
RRM of HuR (lanes 5 and 6). More detailed studies re-
vealed that RRM3 alone retains some ability to bind
SET
 
a
 
/
 
b
 
 and APRIL (lane 8), while the hinge region alone
binds reduced amounts of pp32 (lane 9). However, both
RRM3 and the hinge are required for efficient retention of
all four ligands (lane 7).
We also investigated which regions of the ligands are
necessary for interaction with HuR (Fig. 4 C). Here, in
vitro translated (
 
35
 
S-methionine labeled) full-length and
NH
 
2
 
- and COOH-terminal portions of pp32 (lanes 1–3)
were incubated with immobilized GST-HuR, and the
bound material was gel fractionated and detected by auto-
radiography (lanes 4–6). The pattern of retained polypep-
tides compared with the input reveals that the acidic tail of
pp32 (amino acids 168–249) accounts for its interaction
with GST-HuR (compare lanes 3 and 6), whereas the
NH
 
2
 
-terminal portion (amino acids 1–167) does not bind
(lane 2 vs. 5). Although we were unable to produce com-
parable 
 
35
 
S-labeled subfragments of SET or APRIL for
study, it seems probable that these proteins likewise bind
HuR via their acidic COOH-terminal tails.
 
pp32 and APRIL Appear Nuclear, but Shuttle between 
the Nucleus and the Cytoplasm
 
To determine where HuR interactions with its ligands
might occur in the cell, immunofluorescence experiments
were performed. Confocal microscopy using affinity-puri-
fied antibodies showed that the four HuR binding proteins
differ in their subcellular location in HeLa cells. Antibod-
ies directed against SET
 
a
 
/
 
b
 
 produced nuclear as well as
cytoplasmic staining (Fig. 5, panels 2 and 4), while pp32
and APRIL appeared strictly nuclear (panels 6 and 8, and
10 and 12, respectively). Two other laboratories have re-
ported that pp32 is nuclear (Malek et al., 1990; Matilla et
al., 1997), whereas two have observed cytoplasmic pres-
ence as well (Vaesen et al., 1994; Ulitzur et al., 1997b).
HA-tagged versions of both SET
 
a
 
 and SET
 
b
 
 have previ-
ously been observed to be nuclear when overexpressed in
HeLa cells (Nagata et al., 1998).
Because pp32 and APRIL are nuclear proteins, it was
possible to employ the heterokaryon assay (Schmidt-Zach-
mann et al., 1993) to determine whether they, like HuR,
shuttle between the nucleus and the cytoplasm. pp32 and
APRIL were tagged with the eight amino-acid Flag epi-
topes at their COOH termini, expressed in HeLa cells, and
shown to retain their nuclear location by immunofluores-
cence (Figs. 6 and 7 C, panels 6 and 9). To produce hetero-
karyons, transfected cells were incubated for 3 h with
mouse L929 cells in the presence of cycloheximide (to block
translation) and fused using polyethylene glycol. After an
additional 3-h incubation period (also in the presence of cy-
cloheximide), the coculture was fixed and immunofluores-
cence was performed (Fig. 6). To distinguish the human
and mouse nuclei, the heterokaryons were treated with
Hoechst 33258, which stains the human nucleus uniformly
and the mouse nucleus in a spotted fashion (Moser et al., 1975).
Like HuR (Fan and Steitz, 1998a) (Fig. 6, panel 12),
pp32 (panel 6) and APRIL (panel 9) exhibited shuttling
behavior, appearing in both the human and mouse nuclei
of heterokaryons. Myc-epitope–tagged hnRNP C1 (Na-
kielny and Dreyfuss, 1996), a nonshuttling hnRNP protein,
provided a negative control (panel 3) (Pinol-Roma and
Dreyfuss, 1992). Shuttling may explain the appearance of
pp32 in the cytoplasm of some cell types (Vaesen et al.,
1994; Ulitzur et al., 1997b).
 
pp32 and APRIL Bind CRM1 and Their Nuclear 
Export Is Inhibited by Leptomycin B
 
pp32 and APRIL contain 2 and 3 leucine-rich repeats in
the NH
 
2
 
-terminal portions of their sequences (Fig. 7 A),
Figure 5. In vivo localization of HuR binding proteins. HeLa
cells were fixed, permeabilized, incubated with affinity-purified
polyclonal antiligand antibodies and the 3A2 monoclonal anti–
HuR antibody, and visualized by confocal microscopy. The sec-
ondary antibodies were Texas red–conjugated anti–rabbit and
Alexa 488 conjugated anti-mouse, respectively. 
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respectively. For rev and several other proteins, this motif
constitutes a nuclear export signal (NES) that binds to
CRM1, a nuclear export receptor (Fornerod et al., 1997b).
CRM1, in turn, binds Ran GTP (Fornerod et al., 1997b;
Stade et al., 1997) and several nuclear pore and nucle-
oporin-like proteins [e.g., RIP (Neville et al., 1997), the
CAN/Nup88 complex (Fornerod et al., 1997a), NLP-1
(Farjot et al., 1999)]. LMB, an antifungal and antitumor
agent (Hamamoto et al., 1983a,b; Komiyama et al., 1985),
inhibits nuclear export by covalently modifying a critical
cysteine residue in CRM1 (Kudo et al., 1999), thereby
preventing the formation of the trimeric NES-CRM1-
RanGTP complex (Fornerod et al., 1997b). Experiments
performed both in 
 
Saccharomyces cerevisiae
 
 (Neville and
Rosbash, 1999) and with HeLa extract (Kudo et al., 1998)
have shown the reaction of leptomycin B with CRM1 to be
extremely specific and efficient.
To determine whether their leucine-rich repeats enable
pp32 and APRIL to interact with CRM1, coimmunopre-
cipitation experiments were performed (Fig. 7 B). HeLa
whole-cell extract was precipitated with polyclonal anti–
pp32 or –APRIL antiserum, and immunoblots of the pre-
cipitates were probed with a polyclonal anti–CRM1 anti-
body (Fornerod et al., 1997a). Indeed, CRM1 can be de-
tected in the immunoprecipitates (Fig. 7 B, lanes 1 and 3).
Moreover, complex formation was stimulated in cells
treated with LMB (lanes 2 and 4). While only 
 
z
 
1% of
CRM1 was immunoprecipitated by anti–pp32 or –APRIL
serum when extract was prepared from cells grown in the
absence LMB, 
 
z
 
5% of CRM1 was coimmunoprecipitated
with pp32 and APRIL in extracts derived from cells
Figure 6. pp32- and APRIL-Flag shuttle. HeLa cells were tran-
siently transfected with vectors encoding Myc-hnRNP C1 (Na-
kielny and Dreyfuss, 1996), pp32-Flag, APRIL-Flag, or HuR-
Flag (Fan and Steitz, 1998a), cocultured with mouse L929 cells,
and fused as described (Fan and Steitz, 1998a). Both L929 cells
(before fusion) and heterokaryons were treated with cyclohexim-
ide. Fixed cells were probed with either the M2 anti–Flag mono-
clonal or the 9E10 anti–Myc monoclonal (Sigma-Aldrich); the
secondary antibody was a goat anti–mouse antibody conjugated
to Alexa 488. Cells were also stained with Hoescht 33258 (Sigma-
Aldrich) to distinguish the human and mouse nuclei; the mouse
(but not human) nuclei display a speckled pattern. Figure 7. pp32 and APRIL complex with CRM1, and their nu-
clear export is inhibited by leptomycin B. (A) pp32 and APRIL
contain several rev-like leucine-rich repeats. (B) HeLa whole-cell
extract was prepared from cells grown in either the presence or
absence of 10 ng/ml leptomycin B (12-h treatment). Anti–pp32 or
–APRIL antiserum or 3A2 anti–HuR antibody (in amounts de-
termined to quantitatively precipitate the target protein) was
used for immunoprecipitation and the precipitates were probed
with a polyclonal anti–CRM1 antibody (Fornerod et al., 1997a).
(C) HeLa cells transfected with Myc-hnRNP A1 (Michael et al.,
1995), pp32-Flag, APRIL-Flag, or HuR-Flag (Fan and Steitz,
1998a) were incubated with 10 ng/ml of leptomycin B for 12 h.
They were then fused with L929 cells, permeabilized, and immu-
nofluorescence was performed as reported (Fan and Steitz,
1998a). The antibodies and dye used in this experiment are iden-
tical to those described in Fig. 6. 
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treated with LMB (see Materials and Methods). Immuno-
precipitations performed using the 3A2 anti–HuR (Gal-
louzi et al., 2000) and the 4B10 anti–hnRNP A1 (Pi-
nol-Roma et al., 1988) monoclonal antibodies provided
negative controls. As suggested by their sequences, nei-
ther HuR (Fig. 7 B, lanes 5 and 6) nor hnRNP A1 (data
not shown) detectably interacted with CRM1 in extracts
prepared from cells grown in the absence or presence of
LMB. The converse experiments, in which extracts were
immunoprecipitated with an anti–CRM1 antibody and im-
munoblots of these precipitates were probed with the 3A2
anti–HuR and 4B10 anti–hnRNP A1 antibodies, confirm
these results (data not shown).
We next asked whether leptomycin B inhibits the nu-
clear export of pp32 and APRIL, using HuR and hnRNP
A1, which lack leucine-rich repeats, as controls. Het-
erokaryon fusion experiments were performed as above,
except that for 12 h before incubation of the coculture,
HeLa cells transfected with plasmids encoding pp32-Flag,
APRIL-Flag, HuR-Flag (Fan and Steitz, 1998a), or Myc-
hnRNP A1 (Michael et al., 1995) were incubated with lep-
tomycin B (Fig. 7 C). LMB treatment continued during
the coculture and after fusion. Finally, the cells were fixed
and immunofluorescence was performed. As expected, the
nuclear export of pp32- and APRIL-Flag is significantly
inhibited by leptomycin B. While these proteins migrate
from the human nucleus to the mouse nucleus in untreated
cells (see Fig. 6, panels 6 and 9), they are restricted to the
human nucleus in the presence of LMB (Fig. 7 C, panels 6
and 9). In contrast, Myc-hnRNP A1 and HuR-Flag are ca-
pable of shuttling between the nuclei under either condi-
tion (Fig. 7 C, panels 3 and 12, respectively), confirming
that LMB is specific in targeting CRM1-mediated protein
export. We obtained the same results when HeLa cells
were incubated with LMB for just 3 h before coculturing
(data not shown). These data strongly suggest that CRM1
governs the nuclear export of both pp32 and APRIL.
Leptomycin B Increases HuR’s Interaction with pp32 
and APRIL and Alters HuR’s RNA-binding Activity
Although LMB does not interfere with the nuclear export
of HuR, as judged by heterokaryon fusion assays (Fig. 7),
we reasoned that the abnormal retention of pp32 and
APRIL in the nucleus might nevertheless impact their in-
teraction with HuR. To test this, we examined complex
formation between HuR and its ligands after treatment of
cells with LMB. HeLa cells were grown in the presence of
leptomycin B, whole-cell extract was prepared, and immu-
noprecipitations were performed with anti–pp32, –APRIL,
or –SET antisera. Subsequently, the precipitates were
probed on immunoblots with the 3A2 monoclonal anti–
HuR antibody (Gallouzi et al., 2000). Fig. 8 A shows that,
after LMB treatment, the association of HuR with pp32
and with APRIL increases (compare Fig. 8, lanes 1 with 2,
and 3 with 4). While only a small amount of HuR coimmu-
noprecipitated with pp32 and APRIL in extract prepared
from cells not treated with LMB (z5%), six- and fivefold
more HuR associated with these ligands in extract derived
from LMB-treated cells, respectively (see Materials and
Methods). This is not true of the interaction between
SETa/b and HuR, as the same amount of HuR was coim-
munoprecipitated in the presence and absence of LMB
(compare Fig. 8, lanes 5 and 6). The cellular levels of pp32,
APRIL, and HuR do not change after LMB treatment
(data not shown).
To ask whether increased interaction with its ligands
might alter HuR binding to its target mRNAs, we per-
formed in vivo UV cross-linking in HeLa cells in both the
presence and absence of LMB. Subsequently, nuclear and
cytoplasmic fractions were prepared and poly(A)1 RNA
was purified from each fraction by oligo(dT)-cellulose
chromatography using conditions that release nonco-
valently attached proteins from the RNA (Fig. 8 B, lanes
2–5) (Pinol-Roma et al., 1989). Cross-linked, poly(A)1
RNA/protein complexes were eluted, treated with RNase,
and the presence of HuR was detected by probing immu-
noblots with the 3A2 monoclonal anti–HuR antibody. In
the absence of leptomycin B, HuR cross-linked to only cy-
toplasmic poly(A)1 RNA (Fig. 8 B, lanes 8 and 9), as pre-
viously observed (Gallouzi et al., 2000). We have inter-
preted this result to mean that HuR binds nuclear mRNA
shortly before its export. However, in cells treated with lep-
tomycin B, HuR’s RNA binding profile was altered: HuR
cross-linked equally to poly(A)1 RNA in both the nucleus
and the cytoplasm (lanes 6 and 7, respectively). This is
not true of hnRNP A1, which cross-linked to nuclear
Figure 8. Leptomycin B treatment of HeLa cells results in in-
creased ligand association with HuR, as well as a change in
HuR’s in vivo pattern of RNA binding. (A) HeLa whole-cell ex-
tract was prepared from cells grown either in the presence or ab-
sence of LMB, precipitated with anti–pp32, –APRIL, or –SET
antiserum, and the precipitates were probed with the 3A2 anti–
HuR monoclonal antibody. (B) HeLa cells grown in either the
presence or absence of LMB were subjected to UV irradiation to
induce HuR-RNA cross-links and fractionated into nucleus (N)
and cytoplasm (C) (Pinol-Roma et al., 1989). The poly(A)1
RNA in each fraction was purified on oligo(dT)-sepharose and
degraded with RNase (see Materials and Methods). Subse-
quently, cross-linked HuR was detected by immunoblotting with
the 3A2 antibody. In lanes 2–5, the cells were treated exactly the
same, but the UV treatment was omitted. Lane 1 shows the pro-
tein present in 1% the amount (compared with the other lanes)
of UV-treated extract (total extract, TE) before fractionation.Brennan et al. Ligand Interactions Govern HuR Activity 9
poly(A)1 RNA in cells grown in both the absence (Pinol-
Roma et al., 1989) and presence (data not shown) of LMB.
Recently, several laboratories have suggested that
CRM1 plays a role in mRNA export in S. cerevisiae, Xeno-
pus oocytes, and rat 3Y1 cells (Pasquinelli et al., 1997;
Stade et al., 1997; Watanabe et al., 1999). Therefore, it
might be argued that the change in HuR’s cross-linking
profile after LMB treatment simply represents the interac-
tion of HuR with higher levels of poly(A)1 RNA now in
the nucleus. However, Fig. 9 A shows that the treatment of
HeLa cells with leptomycin B, using the conditions de-
scribed, does not significantly affect the cellular distribu-
tion of total poly(A)1 RNA, as judged by in situ hybrid-
ization using a digoxigenin-labeled oligo(dT) probe and a
rhodamine-conjugated antidigoxigenin antibody (panels
1–4). Quantitation of these results revealed that nuclear
retention of poly(A)1 RNA was only marginally in-
creased (z3%) after LMB treatment (see Materials and
Methods), similar to data reported by other laboratories
for S. cerevisiae or the Xenopus oocyte system (Fischer et
al., 1995; Segref et al., 1997; Neville and Rosbash, 1999).
We conclude that the nuclear cross-linking of HuR to
poly(A)1 RNA in cells treated with LMB represents an in
vivo perturbation of HuR’s activity, apparently through its
interaction with pp32 and/or APRIL. Importantly, while
LMB does not significantly alter the distribution of
poly(A)1 RNA in HeLa cells, it does alter the localization
of an ARE-containing, c-fos mRNA (Fig. 9 B). Cells were
serum stimulated to increase the production of c-fos
mRNA to detectable levels (Greenberg and Ziff, 1984) in
the presence or absence of leptomycin B, fixed, and as-
sayed by in situ hybridization using digoxigenin-labeled
complementary oligonucleotides (see Materials and Meth-
ods). Unlike GAPDH mRNA (compare panel 3 with 4),
c-fos mRNA is selectively retained in the nuclei of LMB-
treated cells (compare panel 1 with 2). This result was ob-
tained using two different probes to c-fos mRNA, one
spanning the 59 untranslated region (UTR) and proximal
coding sequence and one complementary to a region
within the 39 UTR (see Fig. 9, legend). The somewhat
spotted staining pattern of c-fos mRNA has been observed
previously for another short-lived mRNA (Veyrune et al.,
1996). These data reveal that CRM1 is instrumental in the
nuclear export of particular mRNAs (perhaps all ARE-
containing mRNAs) at least under certain conditions.
Collectively, these data argue that increased in vivo in-
teractions with pp32 and APRIL are associated with a
change in HuR’s binding to ARE-containing mRNAs in
cells treated with leptomycin B. Thus, the HuR ligands we
have identified may also modulate HuR function in cells
under normal conditions.
Discussion
We have isolated and characterized four abundant HeLa
cell proteins that specifically associate with HuR: SETa,
SETb, pp32, and APRIL. Coimmunoprecipitation of bind-
ing protein/HuR complexes from glycerol gradient-frac-
tionated, RNase-treated cell extracts suggests that the ag-
gregates are of relatively low molecular weight, arguing
that these proteins (particularly pp32 and APRIL) interact
directly with HuR. All four ligands contain highly acidic
Figure 9. LMB causes c-fos mRNA nuclear retention. (A) HeLa
cells grown with or without LMB (see Materials and Methods)
were fixed, permeabilized, probed with a digoxigenin-labeled
oligo(dT35) probe, and visualized by confocal microscopy with
comparable exposure times. A rhodamine-labeled antidigoxige-
nin antibody (Boehringer) was used for detection. (B) The distri-
bution of c-fos and GAPDH mRNA was examined in HeLa cells
with (2 and 4) and without (1 and 3) LMB treatment, as above.
The 59 digoxigenin-labeled antisense oligonucleotide probe com-
plementary to nucleotides 288–328 of c-fos mRNA (Calbiochem)
(1 and 2) was used at 5 ng/ml with a 1:200 dilution of sheep anti-
digoxigenin Fab-rhodamine antibody (Boehringer). Identical re-
sults were obtained with a c-fos 3 9 untranslated region probe
complementary to nucleotides 3363–3473 (a gift of J.-L. Vey-
rune). Cells in 3 and 4 were treated the same as those in 1 and 2,
except that the hybridization was performed using a digoxigenin-
labeled oligonucleotide complementary to nucleotides 46–85 of
GAPDH mRNA (Calbiochem) as a probe. All antisense probes
gave single bands on Northern blots (not shown). The dotted
lines indicating the nuclear boundaries were constructed from
the phase images of the same cells. Treatment of the fixed cells
with RNase before hybridization with probes yielded no signal,
as in A, 3 and 4. Likewise, no signal was detected with the c-fos
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COOH-terminal tails. Since other human proteins pos-
sessing equally long acidic regions exist [e.g., nucleolin
(Srivastava et al., 1990), nucleosome assembly protein (Si-
mon et al., 1994), transcription factor UBF (Jantzen et al.,
1990)], the selection of these proteins argues that their as-
sociation with HuR reflects more than simply the affinity
of an RNA binding protein for a negatively charged poly-
mer. Only the extreme NH2-terminal sequences vary be-
tween SETa and SETb, indicating that they are splice
variants of one another. pp32 and APRIL exhibit a high
degree of sequence identity (71%) and similarity (81%),
and both contain several rev-like leucine-rich motifs.
Like HuR, pp32 and APRIL are nucleocytoplasmic
shuttling proteins. The leucine-rich repeats present in both
proteins hinted that their nuclear export might occur
through binding of the nuclear export receptor, CRM1.
Coimmunoprecipitation of CRM1 with pp32 and APRIL
and the observation that leptomycin B inhibits their shut-
tling provides confirmation of this export pathway. Inter-
estingly, LMB significantly increases the interaction of
pp32 and APRIL not only with CRM1 (however, see pre-
vious in vitro studies with rev; Askjaer et al., 1998), but
also with HuR. The concomitant increased cross-linking of
HuR to nuclear poly(A)1 RNA suggests that the associa-
tion of HuR with its ligands may modulate HuR’s interac-
tion with its target ARE-containing mRNAs in vivo. At
least under these conditions, CRM1 appears to be instru-
mental in the export of an ARE-containing mRNA (c-fos).
The HuR binding proteins that we have identified ap-
pear in the literature in a remarkable diversity of contexts.
However, a common finding is that SETa, SETb, and pp32
are inhibitors of protein phosphatase 2A (Li et al., 1996;
Saito et al., 1999). Another shared property of the HuR
ligands is their association with cell growth or differentia-
tion. The SET proteins have long been implicated as play-
ers in leukemogenesis. The SET locus was first identified
as a partner in chromosomal translocations with the CAN/
Nup214 locus in patients with acute undifferentiated leu-
kemia (von Lindern et al., 1992). Subsequently, SETb was
observed in a complex with HRX leukemic fusion protein
and PP2A in myeloid leukemic cell extracts (Adler et al.,
1997). SETa and SETb have been shown to associate with
histone/DNA complexes (as template activating factor 1,
TAF1, a and b) and to remodel chromatin structure in
vitro (Okuwaki and Nagata, 1998). Both SETb and pp32
were purified as HLA class II–associated proteins from
human lymphoblastoid cells (Vaesen et al., 1994). pp32 is
expressed at high levels in neoplastic cells, as well as in
normal tissues competent for self-renewal (Walensky et
al., 1993). The pattern of expression of pp32 (LANP) dur-
ing postnatal development suggested a role in the differen-
tiation of cerebellar neurons (Matsuoka et al., 1994). More
recently, pp32 has been observed to inhibit the oncogene-
mediated transformation of rat embryo fibroblasts (Chen
et al., 1996) and to be present in intranuclear aggregates of
mutant ataxin-1 that are associated with (Matilla et al.,
1997), but not essential for (Klement et al., 1998), neural
degeneration. Alternatively, pp32 has been observed to as-
sociate with microtubule-associated proteins, including
MAP2, MAP4, and tau in vitro (mapmodulin; Ulitzur et
al., 1997a). APRIL was only recently identified (Mencinger
et al., 1998) and therefore has not been well studied.
Our localization of the protein domains responsible
for intermolecular contacts with HuR suggests that the
ligands’ common acidic tails are critical (Fig. 4). In the
case of pp32, both its acidic region (amino acids 168–249)
and other portions of the molecule have been previously
demarcated as functionally important. Amino acids 150–
174 of pp32 are absolutely required for inhibiting the ap-
pearance of transformed foci elicited by oncogene pairs
(Brody et al., 1999), whereas the first 147 amino acids of
pp32 (as LANP) interact with ataxin-1 (Matilla et al.,
1997). pp32’s ability to modulate the interaction of micro-
tubule-associated proteins with microtubules (as mapmod-
ulin) has also been assigned to its acidic, COOH-terminal
domain (Ulitzur et al., 1997a). In SET, it is the NH2-termi-
nal region that is required for PP2A inhibitor activity,
whereas the acidic tail contributes to chromatin remodel-
ing in vitro (Saito et al., 1999). The acidic tail of SET is in-
cluded in the SET-CAN fusion implicated in leukemogen-
esis (von Lindern et al., 1992). Thus, some of these ligand
interactions with other cellular molecules would be pre-
dicted to be compatible with, while others would be ex-
pected to compete with, their binding to HuR. This re-
mains to be investigated.
In HuR, deletion of the third RRM alone abrogates rec-
ognition by SETa, SETb, pp32, and APRIL, whereas the
hinge region and RRM3 comprise a minimal substrate for
efficient interaction with these ligands (Fig. 4). Previously,
these two domains have been characterized as being im-
portant for HuR’s ability to shuttle between the nucleus
and the cytoplasm and to bind and stabilize ARE-contain-
ing mRNAs (Ma et al., 1997; Fan and Steitz, 1998a), re-
spectively. Interestingly, the third RRM has been shown to
be important for the functioning of other Hu-family pro-
teins. For instance, RRM3 is not only essential for the full
activity of HuB and HuC in inducing a neuronal pheno-
type upon overexpression in PC12 cells, but it also acted as
a dominant negative protein when cotransfected with wild-
type HuB or HuC, and even when expressed in vivo in cells
of the embryonic central nervous system (Akamatsu et al.,
1999). Similarly, RRM3 and the hinge region of HuD were
observed to be important for neurite-inducing activity in
PC12 cells (Kasashima et al., 1999). While it remains to be
shown that HuB, HuC, and HuD associate with the HuR
ligands we have characterized, the high degree of conser-
vation among the Hu proteins (Okano and Darnell, 1997)
suggests that interaction is likely. Perhaps by binding to
HuR and the other Hu proteins, the HuR ligands facilitate
the stabilization of ARE-containing mRNAs and promote
cellular differentiation.
It was surprising to find that leptomycin B produces
greater cross-linking of HuR to nuclear poly(A)1 RNA
(Fig. 8), even though CRM1 does not directly bind HuR,
and LMB fails to inhibit HuR shuttling (Fig. 7). Specifi-
cally, increased ligand binding induced by LMB might
have been expected to decrease HuR shuttling (perhaps by
sequestering HNS), leading to greater retention of HuR in
the nucleus and therefore greater cross-linking to nuclear
RNA. However, it is not clear from our experiments
whether interaction with its ligands does not in fact alter
the nucleocytoplasmic trafficking of HuR: even though
z50% of HuR is bound by pp32 and APRIL in the pres-
ence of leptomycin B (Fig. 8), shuttling of the remainingBrennan et al. Ligand Interactions Govern HuR Activity 11
free HuR could generate the positive result obtained in the
heterokaryon experiment of Fig. 7. Rather, our observa-
tion of HuR shuttling in the presence of LMB can only be
interpreted to indicate that the HNS of HuR (which con-
tains no leucine-rich repeats) is not recognized by CRM1
(Fig. 7), but instead by some other export receptor.
An alternative explanation for the LMB-induced in-
crease in the cross-linking of HuR to nuclear poly(A)1
RNA is that ligand binding stabilizes HuR’s interaction
with ARE-containing mRNAs. Since in vivo cross-linking
experiments like those in Fig. 8 B have demonstrated that
SETa/b, pp32, and APRIL do not detectably bind RNA
directly (data not shown), the change is likely to be propa-
gated through RRM3 of HuR. Conceivably, the acidic tail
of a ligand could occupy the RNA binding site of RRM3
and thereby displace the poly(A) tail of the mRNA. It is
not clear whether this would decrease or increase HuR
binding to ARE-containing mRNAs since the other two
RRMs of HuR have been reported to have much higher
affinity and to be specific for ARE sequences (Ma et al.,
1997). Further analyses are required. It will also be impor-
tant to establish whether interaction with its ligands under
normal conditions enhances HuR’s binding to ARE-con-
taining mRNAs, as it appears to do in the presence of lep-
tomycin B (Fig. 8 B).
Whatever the mechanism, LMB clearly causes the selec-
tive retention of c-fos, an ARE-containing mRNA, in the
nucleus (Fig. 9 B). Such abnormal nuclear retention could
also be the basis for numerous reports of ARE-containing
mRNA stabilization in cells subjected to various stress
conditions (Andrews et al., 1987; Lindsten et al., 1989;
Hirsch et al., 1995; Gorospe et al., 1998; Levy et al., 1998;
Ming et al., 1998). Clearly, it is most important to investi-
gate in each case whether the mRNA has been trans-
ported to the cytoplasm and is undergoing translation. Al-
though it is possible that leptomycin B inhibits other
components of the nucleocytoplasmic trafficking machin-
ery, the most straightforward interpretation of the results
in Fig. 9 B is that CRM1 is involved in c-fos mRNA export
via HuR interaction with its ligands. Thus, CRM1 should
be considered a potential nuclear export receptor for cer-
tain cellular mRNAs (perhaps all ARE-containing mes-
sages). The possibility that the dominant export pathway
for a particular mRNA may switch, subject to changes in
cellular physiology, is also important to consider.
Our discovery of three HuR ligands (SETa, SETb, and
pp32) that were previously identified as inhibitors of pro-
tein phosphatase 2A (Li et al., 1996; Saito et al., 1999) sug-
gests that a regulatory cascade involving this enzyme influ-
ences ARE-mediated mRNA stability. PP2A is a highly
conserved multimeric serine/threonine phosphatase, af-
fecting a wide variety of cellular functions, including cell
cycle progression, DNA replication, transcription, splicing,
development, and morphogenesis (Millward et al., 1999).
It is dynamic, capable of reversible interconversion be-
tween holoenzyme forms in response to stimulation (Zhu
et al., 1997). PP2A’s ability to dephosphorylate both the
substrates of kinases and kinases themselves appears to be
an important aspect of its function. This phosphatase regu-
lates the activities of several major protein-kinase families,
including those of the AGC subgroup [e.g., protein kinase
B (Andjelkovic et al., 1996), protein kinase C (Hansra et
al., 1996), and p70 S6 kinase (Ballou et al., 1988)], the
calmodulin-dependent kinases (Westphal et al., 1998), and
members of the ERK MAP-kinase pathway (Anderson et
al., 1990; Gomez and Cohen, 1991). The recent demonstra-
tion that expression of MAP kinase–activated protein ki-
nase 2 leads to stabilization of ARE-containing mRNAs
(Dean et al., 1999; Winzen et al., 1999) highlights the im-
portance of particular kinases. Our data argue that in these
signaling cascades, the HuR binding proteins act directly
on HuR, with PP2A placed farther upstream in the path-
way(s) that regulate ARE-mediated mRNA stability.
Since we and others have observed that pp32 and
APRIL are phosphoproteins (data not shown) (Walensky
et al., 1993; Ulitzur et al., 1997b), it is tempting to speculate
that their shuttling, or their interactions with HuR, could
be regulated by phosphorylation. This idea is particularly
attractive since our attempts to identify a phosphorylated
form of HuR have been unsuccessful (data not shown).
Experiments are currently underway to determine whether
particular phosphorylated forms of pp32 and APRIL se-
lectively bind and influence the activity of HuR.
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